Byondis Announces Positive Topline Results of Pivotal Phase III TULIP Study in Patients with HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
June 8, 2018 – Pharmaceutical –
NIJMEGEN, The Netherlands, June 08, 2021 / B3C newswire / — Byondis B.V. today announced positive topline results from the Phase III TULIP study, a multi-center, open-label, randomized clinical trial. The trial compared the efficacy and safety of the companyís antibody-drug conjugate (ADC) [vic-]trastuzumab duocarmazine (SYD985) to physician’s choice treatment in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer (MBC).
The Phase III TULIP study ‘SYD985 vs. Physician’s Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer’ met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant improvement over physicianís choice. PFS is defined as the time from the date of randomization to the date of first documented disease progression or death due to any cause, whichever occurred earlier. The study also demonstrated preliminary supportive overall survival (OS) results.
‘There is considerable unmet medical need in patients with HER2-positive metastatic breast cancer and [vic-]trastuzumab duocarmazine represents a promising potential clinical advance,’ said Byondis Chief Medical Officer Jan Schellens, M.D., Ph.D. ‘We are excited by the topline results of TULIP and indebted to all patients who participated in the clinical studies.’
Byondis CEO Marco Timmers, Ph.D., referred to the studyís culmination as a triumph over adversity. ‘A large trial involving breast cancer patients with advanced disease is difficult in the best of times, but it is especially challenging during a global pandemic. The completion of TULIP is a testament to the dedication of all involved, especially the patients, their families and participating clinical sites.’
Detailed results from TULIP will be published at scientific conferences in due course. Byondis will complete the biological license application (BLA) and intends to submit it before the end of 2021.
With this positive study outcome, Byondis is planning to explore partnerships with pharma and biopharma companies in order to commercialize SYD985 and make it available to patients in need of new treatment options. SYD985 was granted fast track designation by the U.S. Food & Drug Administration in January 2018 based on promising data from heavily pre-treated last-line HER2-positive MBC patients participating in a two-part Phase I clinical trial (SYD985.001).(1)
1. Banerji, Udai, et
al. ‘Trastuzumab Duocarmazine in Locally Advanced and Metastatic Solid Tumours
and HER2-Expressing Breast Cancer: a Phase 1 Dose-Escalation and Dose-Expansion
Study.’ The Lancet Oncology,
Elsevier, 27 June 2019, www.sciencedirect.com/science/article/pii/S1470204519303286.
al. ‘Trastuzumab Duocarmazine in Locally Advanced and Metastatic Solid Tumours
and HER2-Expressing Breast Cancer: a Phase 1 Dose-Escalation and Dose-Expansion
Study.’ The Lancet Oncology,
Elsevier, 27 June 2019, www.sciencedirect.com/science/article/pii/S1470204519303286.
